Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | TRPC6 | Q9Y210 | 4/20 | 0.40 |
| ▸ | QDPR | P09417 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1577511 | 0.89 | GPR119 (0.46) | GPR119PRMT5EGLN1 | |
| SCHEMBL1577799 | 0.89 | GPR119 (0.46) | GPR119PRMT5EGLN1 | |
| SCHEMBL1577922 | 0.88 | GPR119 (0.45) | GPR119PRMT5EGLN1NPC1RAB9A | |
| SCHEMBL1577390 | 0.88 | GPR119 (0.45) | GPR119PRMT5EGLN1 | |
| SCHEMBL1577599 | 0.85 | GPR119 (0.45) | GPR119PRMT5EGLN1 | |
| SCHEMBL14141973 | 0.84 | GPR119 (0.50) | GPR119PRMT5 | |
| SCHEMBL1577527 | 0.83 | GPR119 (0.48) | GPR119PRMT5TRPC6 | |
| SCHEMBL1577687 | 0.80 | ALDH1A1 (0.40) | GPR119PRMT5LMNANPC1RAB9A | |
| SCHEMBL1577759 | 0.78 | DPP4 (0.42) | GPR119LMNANPC1RAB9APTGDR | |
| SCHEMBL1577532 | 0.78 | DPP4 (0.42) | GPR119PRMT5LMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140018537-A1 | GPR119 AGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2014-01-16 | — | — | US | disclosed |
| US-8536176-B2 | GPR119 agonist | NIPPON CHEMIPHAR CO., LTD. (JP) | 2013-09-17 | — | — | US | disclosed |
| US-20110137032-A1 | GPR119 AGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
| EP-2311822-A1 | GPR119 AGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2011-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018537-A1 | GPR119 AGONIST | GPR119, GPR27, GPR52 | GPR119 1/4885PRMT5 839/4885EGLN1 3037/4885 |
| US-20110137032-A1 | GPR119 AGONIST | GPR119, GPR27, GPR52 | GPR119 1/4885PRMT5 839/4885EGLN1 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.